U.S. regulators have awarded fast-track designation to Genzyme’s investigational treatment for Fabry disease. Fabry disease is a rare genetic disorder affecting an approximate 10,000 people around the globe. More information on this treatment and the fast-track program available here. (Source: PharmaTimes Digital, 4/28/15)
You are here: Home / Clinical Trials / Genzyme Receives FDA Fast-Track Status for Fabry Disease Drug
